Dermata Therapeutics Inc(DRMA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 29 at 4:22 AM ET (Korea 9/29 17:22)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -4.39 | Insider Own | 36.31% | Shs Outstand | 4.0M | Perf Week | -2.61% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | 34.1% | Insider Trans | - | Shs Float | 2.6M | Perf Month | -23.29% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | -0.55 | Inst Own | 3.05% | Short Float | 4.69% | Perf Quarter | -13.85% |
| Income | -0.01B | P/S | - | EPS this Y | 73.41% | Inst Trans | 2.2% | Short Ratio | 0.17 | Perf Half Y | -5.08% |
| Sales | 0.00B | P/B | 1.29 | EPS next 5Y | - | ROA | -139.93% | Short Interest | 0.12M | Perf YTD | -51.72% |
| Book/sh | 0.87 | P/C | 1.02 | EPS past 3/5Y | 84.25% 61.24% | ROE | -183.89% | 52W High | -80.92% ($5.87) | Perf Year | -78.42% |
| Cash/sh | 1.1 | P/FCF | - | Sales past 3/5Y | - | ROIC | -239.95% | 52W Low | 17.78% ($0.95) | Perf 3Y | -99.31% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 88.77% | Gross Margin | - | Volatility(W/M) | 6.42% 7.16% | Perf 5Y | -99.99% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.09 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.72 | EPS Q/Q | 55.49% | Profit Margin | - | RSI (14) | 39.8 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.8 | Sales Q/Q | - | SMA20 | -5.72% ($1.19) | Beta | 0.66 | Target Price | $4 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/11 | SMA50 | -11.52% ($1.27) | Rel Volume | 0.03 | Prev Close | $1.14 |
| Employees | 9 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -34.55% - | SMA200 | -24.02% ($1.47) | Avg Volume(3M) | 0.72M | Price | $1.12 |
| IPO | 2021/8/13 | Option/Short | No/Yes | Trades | 129 | Volume | 25,075 | Change | -1.75% |
🧪 Dermata Therapeutics (DMT) is a clinical-stage biotech company headquartered in San Diego, USA, specializing in skin diseases. The company is developing a once-weekly topical acne treatment using DMT310 (brand name: XYNGARI), a novel compound derived from freshwater sponges, and is currently conducting Phase 3 STAR-1 and STAR-2 clinical trials. As an early-stage company with no revenue, it is a small-cap biotech with very high share price volatility depending on clinical trial results.
Over the past 1 year, on the lower side
81% below its 1-year high.
Traded less than usual That is 3% of its average volume.
DRMA has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +73.4% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +77% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 3.0%.
Tap to view numbers
It ranks #553 of 592 in the industry
Based on market cap of $5M.
GRI#552 GRI Bio Inc $5M PER - DRMA#553 Dermata Therapeutics Inc $5M PER - 
PMCB#554 PharmaCyte Biotech Inc $5M PER - 
SXTP#555 60 Degrees Pharmaceuticals Inc $4M PER - 
DCOY#556 Decoy Therapeutics Inc $4M PER - 
FAQ
What kind of company is DRMA?
DRMA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of DRMA?
The market cap of DRMA is approximately $5M, ranking 5,710 within its sector.
What is the 52-week high and low for DRMA?
DRMA has recorded a 52-week high of $5.87 and a low of $0.95.
